Yaquelin Duncan Roberts
Center for Genetic Engineering and Biotechnology
Cuba
Title: Study on security of the perilesional application of CIGB-128A (HeberFERON) in palpebral non melanoma skin cancers with surgical risk and aesthetic implications
Biography
Biography: Yaquelin Duncan Roberts
Abstract
The types of non-melanoma skin cancers more common is the Basal Cells Carcinoma (BCC). This lesion appears generally in white patients starting from the fifth decade of their lives, although it may appear in younger patients. The BCC is the malignant tumor most common of the lids. Frequently, it’s in the inferior lid, near the medial rim. Considering previous results, we decide to use HeberFERON as a therapeutic alternative. The HeberFERON is an interferons mixture with antiproliferatives and anti-angiogenic properties, which has been used in several tumors of the skin, such as BCC, SCC (Squamous Cell Carcinoma), advanced skin Epitheliomas and Hemangiomas, showing a high degree of tolerability, very good cosmetic outcomes, low percent of recurrence and a high index of effectiveness. In this study on security, 10 patients were included with a diagnosis of palpebral BCC and in such study, was demonstrated that the product is safe and endorsed by the adverse events presented, in its majority of light intensity and belonging to the pseudogripal syndrome. Out of 10 patients, 6 (60%) obtained a complete clinical response (CR) and 3 (30%) obtained a Partial clinical Response (PR), representing 90% of objective response (CR+PR). There was not progression. The results show that the HeberFERON could be an important option in the therapeutic arsenal of these diseases of the lids, when the surgical option is not possible, in cases that after the surgery the biopsy confirms the tumor presence in the section margins or in recidivates lesions.